Every 503B outsourcing facility still compounding a GLP-1 drug needs to read the Federal Register, not just the trade press headlines, on this one. On its face, FDA's announcement that it's proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list reads like a narrow technical action. In practice, it's FDA closing the last legal door that some outsourcing facilities were counting on to keep compounding these drugs now that the shortages behind them have ended.
I've spent the last two years watching compounders, med spas, and telehealth platforms build entire business lines around compounded GLP-1s. Some of that was legitimate shortage-era compounding done right. A lot of it was a bet that FDA would either look the other way or find a clinical need to keep the bulk-substance pathway open indefinitely. This proposal answers that bet, and the answer is no.
What FDA Actually Proposed
FDA's announcement is narrower than "banning compounded GLP-1s" but broader than most coverage suggests. The agency is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the list of bulk drug substances that outsourcing facilities registered under section 503B of the Federal Food, Drug, and Cosmetic Act may use to compound drugs without a patient-specific prescription.
To land on that list, a substance has to satisfy the clinical need standard under FDCA section 503B(a)(2)(A)(i). FDA evaluates whether compounding the drug from bulk substance serves a genuine medical purpose that FDA-approved products don't already meet, considering physical and chemical characterization, safety and efficacy data, and whether an approved drug in the needed strength, dosage form, or delivery method already exists. FDA's preliminary conclusion here is that it doesn't. Novo Nordisk and Eli Lilly's approved products, spanning multiple pen configurations, vial strengths, and an oral tablet, already cover the dosing range and administration routes patients need. Once you accept that premise, there's no clinical gap left for a compounded bulk version to fill.
Why the 503B Bulks List Is the Real Story Here
To understand why this proposal matters more than a typical bulks-list update, you need to understand the two separate legal pathways that let outsourcing facilities compound from bulk substances at all. FDA-approved commercial drugs exist for a reason: they've been through the full safety and efficacy review under an NDA or BLA. Compounding is meant to fill gaps around the edges of that system, not to replicate it at scale.
The first pathway is shortage-based compounding under FDCA section 503B(a)(2)(A)(ii). When FDA lists a drug on its drug shortage database, outsourcing facilities may compound essentially a copy of that drug from bulk substances for the duration of the shortage. This is the pathway that let compounders legally produce semaglutide and tirzepatide during 2022 through late 2024, when demand for these drugs outran manufacturing capacity at both Novo Nordisk and Eli Lilly.
The second pathway is the 503B bulks list itself, under section 503B(a)(2)(A)(i). Placement on this list doesn't depend on a shortage at all. If a substance is on the list, outsourcing facilities can compound from it indefinitely, shortage or no shortage, provided FDA has found a genuine clinical need. This is the pathway several parties nominated semaglutide, tirzepatide, and liraglutide for once it became clear the shortages wouldn't last forever. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, according to its drug shortage database, which meant the shortage exception went away for both drugs. The bulks list nomination was the fallback plan. This proposal is FDA taking that fallback off the table.
It's worth sitting with how rarely FDA grants a bulks list petition at all. The 503B bulks list has grown by only a handful of substances since section 503B took effect in 2013, which tells you how high the clinical need bar actually sits in practice. Compounders sometimes talk about bulks list nomination as a routine administrative step. It has never been that, and this proposal is a reminder that FDA treats it as a genuine scientific and clinical determination, not a formality.
Who This Affects
This proposal reaches further than the roughly seventy outsourcing facilities currently registered with FDA under section 503B. Those facilities are the direct legal target, but the downstream effects run through the entire supply chain that built up around compounded GLP-1s over the last three years:
- 503B outsourcing facilities currently compounding semaglutide, tirzepatide, or liraglutide from bulk substances, whether under a personalized-dosing theory or in anticipation of the bulks list nomination succeeding.
- Telehealth platforms and weight-loss clinics that source compounded GLP-1s from outsourcing facilities to fill prescriptions at a lower price point than branded product.
- Medical spas and wellness clinics offering compounded semaglutide or tirzepatide as part of weight-management programs, often at cash-pay prices well below branded list price.
- 503A compounding pharmacies filling patient-specific prescriptions, who face a related but legally distinct set of restrictions I'll get to below.
- Wholesalers and distributors that built logistics relationships around compounded GLP-1 volume during the shortage years.
A KFF survey published in 2024 found that roughly one in eight U.S. adults reported having taken a GLP-1 drug, a demand curve that outpaced what Novo Nordisk and Eli Lilly could manufacture for the better part of two years and created the market conditions this whole compounding episode grew out of. That demand hasn't disappeared. What's disappeared is the shortage that made bulk compounding of these three drugs legal in the first place, and now FDA is proposing to close the backup route too.
The Shortage-Era Compounding Landscape Versus What's Proposed
The table below lays out how the legal pathways for compounding these drugs have shifted, and where the proposed exclusion leaves each one.
| Compounding Pathway | Legal Basis | Requires an Active Shortage? | Status for Semaglutide, Tirzepatide, Liraglutide |
|---|---|---|---|
| Shortage-based compounding (503B) | FDCA §503B(a)(2)(A)(ii) | Yes | Closed — FDA lists both shortages as resolved |
| 503B bulks list nomination | FDCA §503B(a)(2)(A)(i) | No | Proposed for exclusion; FDA finds no clinical need |
| Patient-specific compounding (503A) | FDCA §503A | No, but "essentially a copy" restriction applies | Narrow, case-specific exception only |
| FDA-approved commercial product | NDA/BLA approval | N/A | Available across multiple strengths and delivery forms |
Read across that table and the pattern is clear: every legal pathway that once supported bulk compounding of these three drugs at scale is either already closed or headed there. What survives is patient-specific compounding under section 503A, and even that survives only within tight limits I'd encourage every reader to understand before assuming it's a safe harbor.
What This Doesn't Change
Section 503A compounding pharmacies aren't the direct subject of this proposal, and it's worth being precise about that distinction because I've seen a lot of confusion in how this news is being discussed. The 503B bulks list governs outsourcing facilities. A 503A pharmacy compounding a patient-specific prescription operates under a different statute with its own restriction: it generally cannot compound a drug that is "essentially a copy" of a commercially available FDA-approved drug, unless the prescriber has documented a specific clinical difference for that individual patient, such as an allergy to an inactive ingredient or a documented need for a dosage form the approved product doesn't offer.
That exception has always been narrow, and it was never intended to support standing weight-loss programs compounding semaglutide or tirzepatide for large patient populations on a rolling basis. FDA and the courts have already pushed back hard on compounders who tried to stretch it that far. Several compounders and an industry trade group challenged FDA's determination that the tirzepatide shortage had ended, and a federal court sided with FDA in 2025, upholding the shortage removal. That litigation history matters here because it shows FDA's shortage and bulks-list determinations for these three drugs have already survived a legal challenge once. I wouldn't bet on a different outcome if this proposed exclusion draws a similar suit.
The Compliance Reality for Outsourcing Facilities
If your facility is still compounding semaglutide, tirzepatide, or liraglutide from bulk substance today, here's what I'd want you thinking about before this proposal becomes final.
First, don't wait for the final rule to plan your transition. FDA proposals in this space typically move through a public comment period before a final determination, and comment periods on drug-related determinations commonly run 60 days or more. That sounds like breathing room, but facilities that waited out the shortage-resolution determinations in 2024 and 2025 learned the hard way that "still pending" isn't the same as "still safe." FDA has already shown it will pursue warning letters and import alerts against compounders continuing bulk production of these drugs after a shortage ends, without waiting for every legal question to resolve first.
Second, review whatever legal theory your facility is currently relying on to keep compounding these drugs. If it's a personalized-dosing argument under 503A, get your documentation of individual clinical justification airtight now, not after an FDA investigator asks for it. If it's a bet that the bulks list nomination survives this proposal, that bet just got considerably worse.
Third, if your business model depends on compounded GLP-1 volume, this is the moment to model out what your revenue looks like without it. Facilities that treated compounded semaglutide and tirzepatide as a bridge during the shortage are in a much stronger position than those that built a permanent line of business on the assumption the bridge would stay open. I'd rather see a client make that pivot on their own timeline than on FDA's enforcement timeline.
Fourth, if you want to weigh in, the public comment process exists for a reason. FDA does read comments on bulks list determinations, and a well-documented clinical need argument, submitted with real data rather than a general objection to the proposal, is the only mechanism left to change this outcome before it's final.
What Happens Next
FDA's process from here follows the same track as prior bulks list determinations: a public comment period, review of submitted comments and any new clinical or safety data, and then a final determination that either confirms the exclusion or, in rarer cases, reverses course based on what the record shows. I wouldn't expect a reversal here. FDA's own statement frames this as a clinical need finding grounded in the current availability of approved GLP-1 products across dosage forms, and that's a harder argument to overcome with public comment than a purely procedural objection would be.
In my view, the more interesting question for the industry isn't whether this specific exclusion becomes final. It's what FDA's posture here signals about how the agency will treat future bulks list nominations for other high-demand, high-margin drug classes once their underlying shortages resolve. The agency has now shown, twice in the same product category, that it will treat "commercial product exists in adequate supply and form" as effectively dispositive against a clinical need argument, regardless of price differences between compounded and branded product. That's a standard worth remembering the next time a popular drug class runs short and compounders start planning for what comes after the shortage ends.
Frequently Asked Questions
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.